DMTi-mediated effects on MHC-I gene expression were confirmed in human breast cancer patients who received epigenetic therapy, and suggest the potential for combination strategies of DMTi with immune checkpoint agents, such as PD-L1. This evidence concerns the gene CD274 and breast carcinoma.